Curtiss-Wright (CW) Q2 2026 Earnings Call Transcript

Curtiss-Wright posted Q2 adjusted diluted EPS of $3.72 (+15% YoY) on $924M sales (+5% YoY) and $1.1B new orders (+8% YoY), with a 1.16x book-to-bill and 19.4% adjusted operating margin (+110 bps). Free cash flow rose to $160M (+37% YoY) with 116% FCF conversion, and management raised full-year 2026 guidance: sales to +8% to +9%, adjusted EPS to $15.10–$15.40 (+14% to +16%), and free cash flow to $585M–$605M (record). Defense electronics orders grew nearly 50% YoY and management expects a favorable demand backdrop for 2026–2027, though supply-chain pressures on certain rare earth materials and sequential margin normalization are cited as risks for the near term.

Analysis

CW is still one of the cleaner ways to express “defense + nuclear scarcity value” without owning pure-play platform risk. The business mix is improving, but the bigger second-order implication is pricing power: when a Tier-2/Tier-3 supplier becomes embedded in hard-to-replace programs, backlog quality matters more than headline growth and the multiple can re-rate from cyclical industrial to quasi-critical infrastructure. That said, a lot of the upside is already in the tape; the stock likely trades on whether investors believe the current order run-rate can translate into 2027 earnings rather than on one quarter of margin beats.

The near-term setup is less linear than the headline guidance suggests. Sequentially softer profitability in the next quarter can create a digestion phase, especially if supply-chain friction around rare-earths/chemicals persists and R&D intensity stays ahead of revenue. The key falsifier is any sign that revenue conversion stalls despite the backlog, or that mix normalizes faster than expected and margins stop expanding; that would argue the current premium deserves a pause.

On competitive dynamics, CW’s opportunity set is broader than traditional primes: nontraditional defense entrants need fast-turn, lower-weight, modular subsystems, which plays to CW’s COTS and electronics stack. The less obvious winner is the supply base around nuclear/naval long-lead equipment if public financing accelerates; the loser is lower-value incumbent suppliers that lack qualification or second-source status. Over 6-18 months, the best upside may come from CW becoming a preferred partner for program acceleration, not from any one contract.

Contrarian view: the market may be underestimating how lumpy AP1000 and “Golden Dome” monetization could be, and overestimating how quickly backlog converts to EBITDA. If the first AP1000 order slips or the acquisition pipeline remains frothy, the stock could de-rate even while fundamentals stay solid. In other words, the long thesis is intact, but the next 1-3 months are likely about execution proof, not narrative expansion.

Key Decisions for Investors

• Buy CW on a 3-5% post-earnings pullback; thesis is 12-18 months of above-market EPS compounding with backlog visibility, but near-term upside is best entered on consolidation because Q3 margin commentary creates a natural speed bump.
• Pair trade: long CW / short ITA for 2-3 months. CW has a clearer margin-up-and-backlog-up catalyst path than the broader aerospace-defense basket, while ITA carries more exposure to commercial aero noise and multiple compression if rates stay high.
• If already long CW, hedge with short-dated covered calls 5-8% out of the money against the next 1-2 earnings cycles. Risk/reward favors monetizing elevated sentiment while preserving most of the secular upside.
• Watch item, not a buy: wait for confirmation that AP1000-related orders actually hit before adding aggressively. Falsifier is a missed customer/order timing update or no incremental nuclear contract within the next 1-2 quarters.
• For aggressive expression, buy 6-12 month CW call spreads rather than outright calls. The thesis is a grind higher on earnings revisions, not a quick re-rating, and call spreads reduce theta drag if the stock pauses on sequential margin moderation.